Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketorolac Adjunct to Bupivacaine Block in Thyroid Surgery
NCT05180214Phase 2
Key facts
- Status
- Completed
- Start
- Jan 2021
- Primary completion
- Aug 2021
- Countries
- 1
- Sponsor
- Sohag University
- Modality
- Small Molecules
- Drugs
- ketorolac
- Conditions
- postoperative pain
01
Overview
Phase 2, randomised, double-blind trial of ketorolac in postoperative pain (2 arms), sponsored by Sohag University. Primary endpoint: 1st analgesic requirement at 24 hours. Started Jan 2021; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Bupivacaine
BSCPB with Bupivacaine + Saline
Bupivacaine + Ketorolac
BSCPB with Bupivacaine + Ketorolac
03
Who it enrols
Patients aged 20-50 years, ASA I-II, undergoing thyroid surgery under general anesthesia. Excludes drug abuse, infection at block site, and coagulopathy.
04
Endpoints
Primary
1st analgesic requirement
Secondary
analgesic consumption
postoperative pain
Beyond the preview
Go deeper on NCT05180214.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05180214.